April 24th 2024
The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
VCAM-1 Expression Linked to Poor Survival in Epithelial Ovarian Cancer
November 24th 2016Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.
Novel WEE1 Inhibitor Increases Chemotherapy Efficacy in Ovarian Cancer
November 3rd 2016Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.
Seribantumab Fails to Improve PFS in Ovarian Cancer; Some Patients May Benefit
October 27th 2016Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer. Expression of heregulin and HER2, however, could identify a subset of patients that derive benefit from the therapy.
Rucaparib Demonstrates Strong Activity in BRCA-Mutated Advanced Ovarian Cancer
October 18th 2016The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.
Does Surveillance With CA-125 in Ovarian Cancer Benefit Patients?
September 22nd 2016In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.
ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer
After a review of the published literature, the panel voted on three variants to establish best practices for the utilization of imaging, radiotherapy, and chemotherapy after primary surgery for early-stage endometrial cancer.
Ovarian Cancer Mortality Declining in United States, Europe
September 9th 2016Ovarian cancer mortality rates declined significantly in several parts of the world from 2002 to 2012, according to a new study. Among the main reasons for the decline is the use of oral contraceptives, particular in the United States and European Union.
HIV Infection Decreases Survival in Women With Invasive Cervical Cancer
August 30th 2016HIV infection significantly decreases survival among women with invasive cervical cancer, according to a study conducted in Botswana. This was the case even though most women with HIV received antiretroviral therapy.
ASCO Issues Guideline on Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
August 8th 2016In a new practice guideline, the American Society of Clinical Oncology offered recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction for women with stage IIIC or IV epithelial ovarian cancer.